Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
946 1 |
Ultima descărcare din IBN: 2018-09-29 20:17 |
SM ISO690:2012 KAMMERER, Till, SCHIEGNITZ, Eik, PĂLĂRIE, Victor, TOPALO, Valentin, SCHRÖTER, Andrea, AL-NAWAS, Bilal, KAMMERER, Peer Wolfgang. A biphasic calcium phosphate coating for potential drug delivery affects early osseointegration of titanium implants. In: Journal of Oral Pathology and Medicine, 2017, nr. 1(46), pp. 61-66. ISSN 0904-2512. DOI: https://doi.org/10.1111/jop.12464 |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Journal of Oral Pathology and Medicine | |
Numărul 1(46) / 2017 / ISSN 0904-2512 | |
|
|
DOI: https://doi.org/10.1111/jop.12464 | |
Pag. 61-66 | |
Rezumat | |
Background: Calcium phosphate (CaP) surface coatings may accelerate osseointegration and serve as a drug delivery system for mineral-binding biomolecules. In a pilot study, the impact of a commercially available, thin CaP coating on early osseous bone remodeling was compared with a modern, subtractive-treated rough surface (SLA-like) in an animal trial. Methods: In 16 rabbits, 32 endosseous implants (CaP; n = 16, SLA-like; n = 16) were bilaterally inserted in the proximal tibia after randomization. After 2 and 4 weeks, bone-implant contact (BIC;%) in the cortical (cBIC) and the trabecular bone (sBIC) as well as volume of bone within the screw thread with the highest amount of new-formed bone (area;%) were analyzed. Results: After 2 weeks, cBIC was significantly higher for CaP when compared with SLA-like (58 ± 7% versus 40.4 ± 18%; P = 0.021). sBIC for CaP was 14.7 ± 8% and for SLA-like 7.2 ± 7.8% (P = 0.081). For area, the mean volumes were 82.8 ± 10.8% for CaP and 73.6 ± 22% for SLA-like (P = 0.311). After 4 weeks, cBIC was 42.9 ± 13% for the CaP and 46.5 ± 29.1% for the SLA-like group (P = 0.775). An sBIC of 6.9 ± 9.3% was calculated for CaP and of 12.3 ± 4.8% for SLA-like (P = 0.202). The values for area were 62.3 ± 24.1% for CaP and 50.1 ± 25.9% for SLA-like (P = 0.379). Conclusions: The CaP coating has putative additional advantages in the early osseoconduction phases. It seems suitable for a feasible and clinical applicable bioactivation. |
|
Cuvinte-cheie animal trial, calcium phosphate, drug delivery system, endosseous implant, Bone |
|
|